BERLIN, Oct. 18, 2012 /PRNewswire/ --caprotec bioanalytics GmbH announced today a restructuring of its senior management and the appointment of Dr. Jonathan Turner as Managing Director and Chief Executive Officer. Dr. Turner joins caprotec as a highly regarded pharmaceutical executive and has held a number of senior management positions at global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca PLC and Schering AG.
Prof. Dr. Hubert Koester, Founder and previous Chief Executive Officer of caprotec, will continue to have a key role in the company, assuming responsibility for scientific strategy and technology development as Acting CSO and Chairman of the Scientific Advisory Board.
"Dr. Turner is a well-known and respected executive in the biotech industry. He brings to caprotec a wealth of experience in management and in completing buy- and sell-side transactions between the pharmaceutical industry and biotech companies. His depth of knowledge in drug discovery is ideal to position caprotec's technology with key collaborative partners in the pharmaceutical and agrochemical industries," said Prof. Dr. Koester.
"Prof. Koesterhas demonstrated repeatedly his depth of vision and his ability to turn that into technologies of high commercial value. At caprotec he has nurtured another vision, now sufficiently validated to be transferred into the commercial arena. I look forward to being able to catalyze this step, and welcome that Prof. Koester will continue to support the company with his scientific expertise, drive, world-wide contacts, and the support of our broad-based investors," said Dr. Turner.
Prior to joining caprotec, Dr. Turner was Senior Vice President at XL Techgroup, a technology developer and equity firm connecting investors and biotech companies operating globally. Prior to that, Dr. Turner held senior level management position in the pharmaceutical industry, including Corporate Head of Business Development and Licensing at Boehringer Ingelheim, Germany; Global Director of Respiratory and Inflammation Discovery Alliances at AstraZeneca PLC, UK; and Departmental Head of CNS Research at Schering AG, Berlin. He earned his doctoral degree in neuropharmacology at the University of St. Andrews, UK and lectured in psychiatry at the University of Newcastle, UK. He has been a member of several Supervisory Boards in the German biotech industry, has been responsible for two large international industry-academia consortia and has authored multiple peer reviewed publications.
About caprotec bioanalytics
caprotec bioanalytics is headquartered in Berlin, Germany and focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core feature consists of small, tri-functional molecules called Capture CompoundsTM which enable the identification of proteins that interact with drugs, or other small molecules, directly from complex biological samples. This world-leading platform is protected by a broad patent portfolio and has enormous potential in proteome analysis, drug development and the identification of biomarkers. This potential is being realized in collaborative partnerships within the global pharmaceutical and agrochemical industries. caprotec's current investors are Creathor Venture, Bad Homburg; IBB Beteiligungsgesellschaft mbH, Berlin; KfW Mittelstandsbank, Berlin; LBBW Venture Capital GmbH, Stuttgart and multiple private investors.
SOURCE caprotec bioanalytics